Log-in
Randomisation system
log-in to secure server here

Painting The Reply of the Zaporozhian Cossacks to Sultan of Turkey by Ilya Yefimovich Repin

ISD Scotland

A randomised phase II study evaluating cediranib vs. cediranib and saracatanib in patients with relapsed metastatic clear cell renal cancer (COSAK)

This is a double blind randomised phase II study. Patients will be randomised to receive cediranib and saracatanib or cediranib and placebo. Patients will be assessed at the same frequency in both arms and progression will be assessed against the RECIST criteria.

If you require any help, please contact:

Joanna Dunlop
Email: joanna.dunlop@nhs.net

Randomisation service provided by: Sealed Envelope™.com